JOP20220322A1 - مثبطات pcsk9 وطرق استخدامها لعلاج الاضطرابات المرتبطة بالكوليسترول - Google Patents

مثبطات pcsk9 وطرق استخدامها لعلاج الاضطرابات المرتبطة بالكوليسترول

Info

Publication number
JOP20220322A1
JOP20220322A1 JOJO/P/2022/0322A JOP20220322A JOP20220322A1 JO P20220322 A1 JOP20220322 A1 JO P20220322A1 JO P20220322 A JOP20220322 A JO P20220322A JO P20220322 A1 JOP20220322 A1 JO P20220322A1
Authority
JO
Jordan
Prior art keywords
methods
related disorders
pcsk9 inhibitors
cholesterol
treat cholesterol
Prior art date
Application number
JOJO/P/2022/0322A
Other languages
Arabic (ar)
English (en)
Inventor
Ian Matthew Bridges
Andrea Ruzza
Christopher Kurtz
Andrew W Hamer
Huei Wang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20220322A1 publication Critical patent/JOP20220322A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JOJO/P/2022/0322A 2020-05-29 2022-11-27 مثبطات pcsk9 وطرق استخدامها لعلاج الاضطرابات المرتبطة بالكوليسترول JOP20220322A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032451P 2020-05-29 2020-05-29
PCT/US2021/034489 WO2021243002A1 (en) 2020-05-29 2021-05-27 Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders

Publications (1)

Publication Number Publication Date
JOP20220322A1 true JOP20220322A1 (ar) 2022-11-27

Family

ID=78722769

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2022/0322A JOP20220322A1 (ar) 2020-05-29 2022-11-27 مثبطات pcsk9 وطرق استخدامها لعلاج الاضطرابات المرتبطة بالكوليسترول

Country Status (11)

Country Link
US (1) US20230235085A1 (https=)
EP (1) EP4157887A4 (https=)
JP (1) JP2023527542A (https=)
CN (1) CN115916838A (https=)
AR (1) AR122180A1 (https=)
AU (1) AU2021281256A1 (https=)
CA (1) CA3179316A1 (https=)
IL (1) IL298375A (https=)
JO (1) JOP20220322A1 (https=)
TW (1) TW202210524A (https=)
WO (1) WO2021243002A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN121693519A (zh) 2023-08-14 2026-03-17 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2025265012A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprising anti-pcsk9 antbodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
PL3169353T3 (pl) * 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)

Also Published As

Publication number Publication date
WO2021243002A1 (en) 2021-12-02
IL298375A (en) 2023-01-01
TW202210524A (zh) 2022-03-16
JP2023527542A (ja) 2023-06-29
CA3179316A1 (en) 2021-12-02
AU2021281256A1 (en) 2022-12-22
EP4157887A1 (en) 2023-04-05
US20230235085A1 (en) 2023-07-27
CN115916838A (zh) 2023-04-04
AR122180A1 (es) 2022-08-24
EP4157887A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
JOP20220322A1 (ar) مثبطات pcsk9 وطرق استخدامها لعلاج الاضطرابات المرتبطة بالكوليسترول
AU2017258105A1 (en) Methods for treating patients with familial hypercholesterolemia
EP4403213A3 (en) Methods for reducing cardiovascular risk
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2010004454A (es) Anti-proproteina convertasa subtilisina/kexina tipo 9 y metodos para tratar trastornos de lipidos y colesterol.
EA202091144A1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2012000817A (es) Tratamiento para desordenes del higado con inhibidores pi3k.
BR112015002285A2 (pt) métodos de tratamento de câncer utilizando 3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona
ATE438650T2 (de) Proteasominhibitoren und verfahren zu deren anwendung
IL184678A0 (en) Proteasome inhibitors and methods of using the same
MX365007B (es) Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
PH12022551052A1 (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
MX2021013318A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
MX2024005647A (es) Tratamiento de trastornos hepaticos con un agonista del thr-\03b2.
MX2023001481A (es) Metodos para tratar pacientes con hipercolesterolemia refractaria.
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
MX2024015041A (es) Fitusiran para el tratamiento de la hemofilia a y b
UA88771C2 (ru) Ингибиторы протеасомы и способ их применения (варианты)
WO2024259171A3 (en) Keap1 inhibitors for use in the treatment of immunological disorders
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
MX2022003236A (es) Bencimidazol carboxamidas sustituidas y su uso en el tratamiento de trastornos medicos.
WO2022261467A9 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy